Quality-of-life assessment in schizophrenia: The unfulfilled promise

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 5, 2011, Pages 491-493

  Awad, A George ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b International Society of CNS Clinical Trials and Methodology (ISCTM)   (United States)

^c HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

clinical care; clinical trials; cost utility; quality of life; quality of life assessment; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 80053472445     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.61     Document Type: Review

References (15)

1. Awad AG, Voruganti LNP. Measuring quality of life of patients with schizophrenia. Pharmacoeconomics 11:32-47 (1997). (Pubitemid 27032248)
2. Lehman A. The well-being of chronic mental patients; assessing their quality of life. Arch. Gen. Psychiatry 40, 369-370 (1983).
3. Bachrach LL. Deinstitutionalization: an analytic review and sociological perspective: Rochville (MD) National Institute of Mental Health 1976. Gen. Hosp. Psychiatry 7(3), 239-248 (1985).
4. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trails. Hosp. Comm. Psychiatry 43, 262-265 (1992).
5. Awad AG, Voruganti LNP. International research in psychosis: issues related to the assessment of quality of life. Schizophr. Bull. 26, 557-564 (2000).
6. Awad AG, Voruganti LNP, Heselgrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual. Life Res. 6, 21-26 (1997). (Pubitemid 27110091)
7. Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia-an update. Pharmacoeconomics (2011) (In Press).
8. Awad AG, Voruganti LNP. New antipsychotics, compliance, quality of life and subjective tolerability-are patients better off? Can. J. Psychiatry 49, 297-302 (2004). (Pubitemid 38724634)
9. Awad AG, Voruganti LNP. Antipsychotic medications, schizophrenia and the issue of quality of life. In: Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. Ritsner M, Awad AG (Eds). Springer, The Netherlands, 307-319 (2007).
10. Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18, 877-893 (2004). (Pubitemid 39612017)
11. Davies LM, Drummond MF. The economic burden of schizophrenia. Schizophr. Bull. 14, 522-525 (1990).
12. Awad AG, Voruganti LNP. Cost-utility analysis in schizophrenia. J. Clin. Psychiatry 60(Suppl. 3), 22-29 (1999).
13. Voruganti LNP, Awad AG et al. Assessing health utilities in schizophrenia-a feasibility study. Pharmacoeconomics 17, 273-286 (2000). (Pubitemid 30214634)
14. Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics 28, 1109-1121 (2010).
15. Dernovsek MZ, Prevolnik-Rupel V, Tavcar R. Cost-utility analysis-research and practical application. In: Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. Ritsner M, Awad AG (Eds). Springer, The Netherlands, 373-384 (2007).